化疗对小细胞肺癌患者血管内皮生长因子及外周血T淋巴细胞亚群的影响

Impact of Chemotherapy on VEGF and Peripheral Blood T- lymphocyte Subsets of Patients with Small Cell Lung Cancer

目的探讨化疗对小细胞肺癌患者血管内皮生长因子(VEGF)及外周血T淋巴细胞亚群的影响。方法选取2013年1月—2014年1月在佛山市顺德区第一人民医院就诊并接受化疗的48例小细胞肺癌患者作为观察组,另选取健康献血者和佛山市顺德区第一人民医院健康工作人员共48例作为对照组。观察组患者给予卡铂联合依托泊苷化疗,连续治疗3周为1个疗程。记录对照组及观察组化疗前后血清VEGF水平及外周血T淋巴细胞亚群,其中外周血T淋巴细胞亚群包括CD+3细胞分数、CD+4细胞分数、CD+8细胞分数及CD+4/CD+8细胞比值。结果观察组化疗前血清VEGF水平高于对照组(P<0.05);观察组患者化疗后血清VEGF水平低于化疗前(P<0.05)。对照组CD+3细胞分数、CD+4细胞分数、CD+8细胞分数及CD+4/CD+8细胞比值高于观察组化疗前,观察组化疗后CD+3细胞分数、CD+4细胞分数、CD+8细胞分数及CD+4/CD+8细胞比值高于化疗前(P<0.05)。结论化疗能有效降低小细胞肺癌患者血清VEGF水平、改善患者免疫调节能力。

Objective To study the impact of chemotherapy on VEGF and peripheral blood T- lymphocyte subsets of patients with small cell lung cancer. Methods From January 2013 to January 2014 in the First People＇ s Hospital of Shunde District,Foshan,a total of 48 patients with small cell lung cancer were selected as observation group,48 healthy blood donors or hospital worker were selected as control group. Patients of observation group were given carboplatin combined with etoposide,continuously treated for 3 weeks as a course. Serum VEGF level and peripheral blood T- lymphocyte subsets（ including CD＋3cell percentage,CD＋4cell percentage,CD＋8cell percentage and CD＋4/ CD＋8cell ratio） of the two groups were recorded before and after treatment. Results The serum VEGF level of observation group before treatment was statistically significantly higher than that of control group（ P〈0. 05）,and serum VEGF level of observation group after treatment was statistically significantly higher than that before treatment（ P〈0. 05）. CD＋3cell percentage,CD＋4cell percentage,CD＋8cell percentage and CD＋4/ CD＋8cell ratio of observation group before treatment were statistically significantly lower than those of control group（ P〈0. 05）,and above index of observation group after treatment were statistically significantly higher than those before treatment（ P〈0. 05）.Conclusion Chemotherapy can effectively reduce serum VEGF level and improve the immunoregulation capability of patients with small cell lung cancer.